Literature DB >> 32832832

Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors.

Carl Koschmann1, Yi-Mi Wu1, Chandan Kumar-Sinha1, Robert Lonigro1, Pankaj Vats1, Katayoon Kasaian1, Marcin Cieslik1, Xuhong Cao1, Bailey Anderson1, Kevin Frank1, Lili Zhao1, John R Prensner2, Andrew H Zureick1, Jessica Everett1, Brendan Mullan1, Bernard Marini1, Sandra Camelo-Piragua1, Sriram Venneti1, Paul McKeever1, Kathryn McFadden1, Andrew P Lieberman1, Marcia Leonard1, Cormac O Maher1, Hugh Garton1, Karin Muraszko1, Patricia Robertson1, Dan Robinson1, Arul M Chinnaiyan1, Rajen Mody1.   

Abstract

PURPOSE: Brain tumors have become the leading cause of cancer-related mortality in young patients. Novel effective therapies on the basis of the unique biology of each tumor are urgently needed. The goal of this study was to evaluate the feasibility, utility, and clinical impact of integrative clinical sequencing and genetic counseling in children and young adults with high-risk brain tumors. PATIENTS AND METHODS: Fifty-two children and young adults with brain tumors designated by the treating neuro-oncologist to be high risk (> 25% chance for treatment failure; mean age, 10.2 years; range, 0 to 39 years) were enrolled in a prospective, observational, consecutive case series, in which participants underwent integrative clinical exome (tumor and germline DNA) and transcriptome (tumor RNA) sequencing and genetic counseling. Results were discussed in a multi-institutional brain tumor precision medicine teleconference.
RESULTS: Sequencing revealed a potentially actionable germline or tumor alteration in 25 (63%) of 40 tumors with adequate tissue, of which 21 (53%) resulted in an impact on treatment or change of diagnosis. Platelet-derived growth factor receptor or fibroblast growth factor receptor pathway alterations were seen in nine of 20 (45%) glial tumors. Eight (20%) sequenced tumors harbored an oncogenic fusion isolated on RNA sequencing. Seventeen of 20 patients (85%) with glial tumors were found to have a potentially actionable result, which resulted in change of therapy in 14 (70%) patients. Patients with recurrent brain tumors receiving targeted therapy had a median progression-free survival (from time on therapy) of 4 months.
CONCLUSION: Selection of personalized agents for children and young adults with highrisk brain tumors on the basis of integrative clinical sequencing is feasible and resulted in a change in therapy in more than two thirds of children and young adults with high-risk glial tumors.

Entities:  

Year:  2018        PMID: 32832832      PMCID: PMC7434092          DOI: 10.1200/po.17.00133

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


  32 in total

1.  The somatic genomic landscape of glioblastoma.

Authors:  Cameron W Brennan; Roel G W Verhaak; Aaron McKenna; Benito Campos; Houtan Noushmehr; Sofie R Salama; Siyuan Zheng; Debyani Chakravarty; J Zachary Sanborn; Samuel H Berman; Rameen Beroukhim; Brady Bernard; Chang-Jiun Wu; Giannicola Genovese; Ilya Shmulevich; Jill Barnholtz-Sloan; Lihua Zou; Rahulsimham Vegesna; Sachet A Shukla; Giovanni Ciriello; W K Yung; Wei Zhang; Carrie Sougnez; Tom Mikkelsen; Kenneth Aldape; Darell D Bigner; Erwin G Van Meir; Michael Prados; Andrew Sloan; Keith L Black; Jennifer Eschbacher; Gaetano Finocchiaro; William Friedman; David W Andrews; Abhijit Guha; Mary Iacocca; Brian P O'Neill; Greg Foltz; Jerome Myers; Daniel J Weisenberger; Robert Penny; Raju Kucherlapati; Charles M Perou; D Neil Hayes; Richard Gibbs; Marco Marra; Gordon B Mills; Eric Lander; Paul Spellman; Richard Wilson; Chris Sander; John Weinstein; Matthew Meyerson; Stacey Gabriel; Peter W Laird; David Haussler; Gad Getz; Lynda Chin
Journal:  Cell       Date:  2013-10-10       Impact factor: 41.582

Review 2.  Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections.

Authors:  Roland Nau; Fritz Sörgel; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

3.  Transforming fusions of FGFR and TACC genes in human glioblastoma.

Authors:  Devendra Singh; Joseph Minhow Chan; Pietro Zoppoli; Francesco Niola; Ryan Sullivan; Angelica Castano; Eric Minwei Liu; Jonathan Reichel; Paola Porrati; Serena Pellegatta; Kunlong Qiu; Zhibo Gao; Michele Ceccarelli; Riccardo Riccardi; Daniel J Brat; Abhijit Guha; Ken Aldape; John G Golfinos; David Zagzag; Tom Mikkelsen; Gaetano Finocchiaro; Anna Lasorella; Raul Rabadan; Antonio Iavarone
Journal:  Science       Date:  2012-07-26       Impact factor: 47.728

4.  Dissecting the genomic complexity underlying medulloblastoma.

Authors:  David T W Jones; Natalie Jäger; Marcel Kool; Thomas Zichner; Barbara Hutter; Marc Sultan; Yoon-Jae Cho; Trevor J Pugh; Volker Hovestadt; Adrian M Stütz; Tobias Rausch; Hans-Jörg Warnatz; Marina Ryzhova; Sebastian Bender; Dominik Sturm; Sabrina Pleier; Huriye Cin; Elke Pfaff; Laura Sieber; Andrea Wittmann; Marc Remke; Hendrik Witt; Sonja Hutter; Theophilos Tzaridis; Joachim Weischenfeldt; Benjamin Raeder; Meryem Avci; Vyacheslav Amstislavskiy; Marc Zapatka; Ursula D Weber; Qi Wang; Bärbel Lasitschka; Cynthia C Bartholomae; Manfred Schmidt; Christof von Kalle; Volker Ast; Chris Lawerenz; Jürgen Eils; Rolf Kabbe; Vladimir Benes; Peter van Sluis; Jan Koster; Richard Volckmann; David Shih; Matthew J Betts; Robert B Russell; Simona Coco; Gian Paolo Tonini; Ulrich Schüller; Volkmar Hans; Norbert Graf; Yoo-Jin Kim; Camelia Monoranu; Wolfgang Roggendorf; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Andreas von Deimling; Olaf Witt; Eberhard Maass; Jochen Rössler; Martin Ebinger; Martin U Schuhmann; Michael C Frühwald; Martin Hasselblatt; Nada Jabado; Stefan Rutkowski; André O von Bueren; Dan Williamson; Steven C Clifford; Martin G McCabe; V Peter Collins; Stephan Wolf; Stefan Wiemann; Hans Lehrach; Benedikt Brors; Wolfram Scheurlen; Jörg Felsberg; Guido Reifenberger; Paul A Northcott; Michael D Taylor; Matthew Meyerson; Scott L Pomeroy; Marie-Laure Yaspo; Jan O Korbel; Andrey Korshunov; Roland Eils; Stefan M Pfister; Peter Lichter
Journal:  Nature       Date:  2012-08-02       Impact factor: 49.962

5.  Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.

Authors:  Adam M Fontebasso; Simon Papillon-Cavanagh; Jeremy Schwartzentruber; Hamid Nikbakht; Noha Gerges; Pierre-Olivier Fiset; Denise Bechet; Damien Faury; Nicolas De Jay; Lori A Ramkissoon; Aoife Corcoran; David T W Jones; Dominik Sturm; Pascal Johann; Tadanori Tomita; Stewart Goldman; Mahmoud Nagib; Anne Bendel; Liliana Goumnerova; Daniel C Bowers; Jeffrey R Leonard; Joshua B Rubin; Tord Alden; Samuel Browd; J Russell Geyer; Sarah Leary; George Jallo; Kenneth Cohen; Nalin Gupta; Michael D Prados; Anne-Sophie Carret; Benjamin Ellezam; Louis Crevier; Almos Klekner; Laszlo Bognar; Peter Hauser; Miklos Garami; John Myseros; Zhifeng Dong; Peter M Siegel; Hayley Malkin; Azra H Ligon; Steffen Albrecht; Stefan M Pfister; Keith L Ligon; Jacek Majewski; Nada Jabado; Mark W Kieran
Journal:  Nat Genet       Date:  2014-04-06       Impact factor: 38.330

Review 6.  Capturing the molecular and biological diversity of high-grade astrocytoma in genetically engineered mouse models.

Authors:  Lionel M L Chow; Suzanne J Baker
Journal:  Oncotarget       Date:  2012-01

7.  Emerging landscape of oncogenic signatures across human cancers.

Authors:  Giovanni Ciriello; Martin L Miller; Bülent Arman Aksoy; Yasin Senbabaoglu; Nikolaus Schultz; Chris Sander
Journal:  Nat Genet       Date:  2013-10       Impact factor: 38.330

8.  Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing.

Authors:  Philipp Euskirchen; Franck Bielle; Karim Labreche; Wigard P Kloosterman; Shai Rosenberg; Mailys Daniau; Charlotte Schmitt; Julien Masliah-Planchon; Franck Bourdeaut; Caroline Dehais; Yannick Marie; Jean-Yves Delattre; Ahmed Idbaih
Journal:  Acta Neuropathol       Date:  2017-06-21       Impact factor: 17.088

9.  Activating ESR1 mutations in hormone-resistant metastatic breast cancer.

Authors:  Dan R Robinson; Yi-Mi Wu; Pankaj Vats; Fengyun Su; Robert J Lonigro; Xuhong Cao; Shanker Kalyana-Sundaram; Rui Wang; Yu Ning; Lynda Hodges; Amy Gursky; Javed Siddiqui; Scott A Tomlins; Sameek Roychowdhury; Kenneth J Pienta; Scott Y Kim; J Scott Roberts; James M Rae; Catherine H Van Poznak; Daniel F Hayes; Rashmi Chugh; Lakshmi P Kunju; Moshe Talpaz; Anne F Schott; Arul M Chinnaiyan
Journal:  Nat Genet       Date:  2013-11-03       Impact factor: 38.330

10.  Phosphoglycerate dehydrogenase induces glioma cells proliferation and invasion by stabilizing forkhead box M1.

Authors:  Jinlong Liu; Shaolei Guo; Qingzhi Li; Lixuan Yang; Zhibai Xia; Longjuan Zhang; Zhengsong Huang; Nu Zhang
Journal:  J Neurooncol       Date:  2012-12-11       Impact factor: 4.130

View more
  4 in total

Review 1.  Molecular alterations of low-grade gliomas in young patients: Strategies and platforms for routine evaluation.

Authors:  Iman Dandapath; Rituparna Chakraborty; Kavneet Kaur; Swati Mahajan; Jyotsna Singh; Mehar C Sharma; Chitra Sarkar; Vaishali Suri
Journal:  Neurooncol Pract       Date:  2021-08-23

Review 2.  The Clinical Applications of Liquid Biopsies in Pediatric Brain Tumors: A Systematic Literature Review.

Authors:  Ladina Greuter; Nicole Frank; Raphael Guzman; Jehuda Soleman
Journal:  Cancers (Basel)       Date:  2022-05-28       Impact factor: 6.575

3.  Electronic DNA Analysis of CSF Cell-free Tumor DNA to Quantify Multi-gene Molecular Response in Pediatric High-grade Glioma.

Authors:  Amy K Bruzek; Karthik Ravi; Ashwath Muruganand; Jack Wadden; Clarissa May Babila; Evan Cantor; Leo Tunkle; Kyle Wierzbicki; Stefanie Stallard; Robert P Dickson; Ian Wolfe; Rajen Mody; Jonathan Schwartz; Andrea Franson; Patricia L Robertson; Karin M Muraszko; Cormac O Maher; Hugh J L Garton; Tingtin Qin; Carl Koschmann
Journal:  Clin Cancer Res       Date:  2020-10-21       Impact factor: 12.531

4.  Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients.

Authors:  Elisa Izquierdo; Paula Proszek; Giulia Pericoli; Sara Temelso; Matthew Clarke; Diana M Carvalho; Alan Mackay; Lynley V Marshall; Fernando Carceller; Darren Hargrave; Birgitta Lannering; Zdenek Pavelka; Simon Bailey; Natacha Entz-Werle; Jacques Grill; Gilles Vassal; Daniel Rodriguez; Paul S Morgan; Tim Jaspan; Angela Mastronuzzi; Mara Vinci; Michael Hubank; Chris Jones
Journal:  Neurooncol Adv       Date:  2021-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.